37 results about "Immune modulator" patented technology

CD318 (CDCP1) is a CUB-domain containing cell surface protein over-expressed in major types of cancers to promote tumor growth and metastasis. The present disclosure relates to the identification and characterization of novel anti-CD318 monoclonal antibodies. By targeting CD318 as a tumor associated antigen, the disclosure further relates to different modalities of using anti-CD318 antibodies to kill cancer cells, including CD318 antibody based immunocytokines, CD318 antibody-based immune modulators, and CD318 antibody drug conjugates.

The invention belongs to the technical field of biological medicines, and particularly relates to a compound as shown in a formula (I), pharmaceutically acceptable salt, deuterated substance, stereoisomer, tautomer or a mixture of the pharmaceutically acceptable salt, the deuterated substance, the stereoisomer and the tautomer, and application of the compound as an IKZF1 and IKZF3 double-target immunomodulator.

The present disclosure relates in some aspects to constructs and methods for increasing solid organ transplant survival. More specifically, aspects of the present disclosure relate to methods and constructs for administering full-length PD-L1 and one immune modulators, such as one or more of: CTLA-4, Qa-1d, HLA-E, HLA-G, CMTM6, and Indolamine-2,3-dioxygenase (IDO), by ex vivo perfusion in order to increase solid organ transplant survival.

The present disclosure provides antibodies or antigen-binding fragments thereof specific for prolactin receptor (PRLR). Such antibodies or antigen-binding fragments can be used in many pharmaceutical applications, for example, as anti-cancer agents and / or immune modulators. The present disclosure also concerns methods of making the antibodies or antigen-binding fragments described herein as well as compositions comprising such antibodies or antigen-binding fragments. The present disclosure further relates to nucleic acid molecules encoding such antibodies or antigen-binding fragments. In addition, the present disclosure provides therapeutic and / or diagnostic uses of such antibodies or antigen-binding fragments.

The present invention relates to the field of medical therapy of lesions detrimental to a body. The system is capable of treatment with a non-invasive, ionizing kV energy radiation source. Locally focused energy can be used to definitively treat, or as an adjuvant to enhance immune modulators, to eliminate tumors. Distributed external beam entry points produce a significant advantageous dose profile at depth as intersecting beams accumulate in a narrow focus to treat a selected volume. Targeted disease may have enhanced sensitivity to the radiation by taking up an ionizing-radiation, treatment-localizing agent. This increases the effectiveness of an energy dose in the lesion. The pattern of beam output is effectively directed towards a desired location and kV x-rays traveling towards undesired locations, such as healthy tissue, are quenched. Targeting a lesion within the body with volumetrically discrete energy dose deposition can beneficially impact harmful lesions. Aiming the beam at a pathologic target is done while moving an x-ray source mechanically around a patient to distribute surface dose. The purpose of the focused energy deposition is to destroy and disable pathologic physiology, such as malignant masses. More specifically this invention relates to a system, which optimizes delivery of ionizing kV beams to a lesion alone or one containing treatment-localizing agents in higher concentration than the surrounding normal tissues. Thereby an optimal delivery of ionizing radiation becomes more destructive to a mass of abnormal cells upon interaction with the targeted site.

Compounds, pharmaceutical compositions and methods are provided for reprogramming M2-like macrophages to M1-like macrophages, which reverses the antifibrotic to profibrotic shift observed during the course of fibrotic diseases and certain cancers. The compounds comprise an immune modulator that targets a pattern recognition receptor of a cell and are specific to the cells of interest through the incorporation of a targeting moiety (e.g., folate or a functional fragment or analog thereof). Releasable and / or non-releasable linkers can be included and engineered to facilitate the optimal delivery of the immune modulator. The compounds and compositions can be employed in one or more methods of treatment for fibrotic diseases and / or cancers.

Synthetic oligosaccharides and mixtures thereof which resemble polysaccharides produced by plants, yeast and other fungi, bacteria, and algae are described. The oligosaccharides and compositions provided herein are useful as synbiotics, prebiotics, immune modulators, digestion aids, and food additives.

The disclosure provides fusion proteins specific for both CD137 and GPC3, which fusion protein can be used to co-stimulate lymphocyte activation in a GPC3-target-dependent manner. Such fusion proteins can be used in many pharmaceutical applications, for example, as anti-cancer agents and / or immune modulators for the treatment or prevention of human diseases such as a variety of tumors. The present disclosure also concerns methods of making the fusion proteins described herein as well as compositions comprising such fusion proteins. The present disclosure further relates to nucleic acid molecules encoding such fusion proteins and to methods for generation of such fusion proteins and nucleic acid molecules. In addition, the application discloses therapeutic and / or diagnostic uses of such fusion proteins as well as compositions comprising one or more of such fusion proteins.

A nutritional supplement includes one or more immune modulators that support a subject's cellular immunity, as well as ingredients that enhance the production and use of nitric oxide by the subject's body to better regulate the subject's cellular immunity. Such a nutritional supplement may include nano-fraction immune modulators, transfer factor, or plant transfer factor, as well as sufficient amounts of vitamin B9 and vitamin B12 to increase endothelial nitric oxide synthetase activity in a body of a subject. Methods for increasing endothelial nitric oxide synthetase activity in the body of a subject are also disclosed.

The present disclosure provides a compound of Formula (I), its stereoisomers, intermediates, or pharmaceutically acceptable salt thereof and a method of preparation of the same. In addition, the present disclosure provides a pharmaceutical composition comprising the compound of Formula (I) and its stereoisomers, intermediates, or pharmaceutically acceptable salt thereof; a pharmaceutically acceptable carrier; and optionally, in combination with one or more other pharmaceutical compositions. Further, the present disclosure provides a method for prevention or treatment of neurodegenerative disease or for treatment of a condition mediated by aggregation of tau, by administering an effective amount of the compound of Formula (I), its stereoisomers, intermediates, pharmaceutically acceptable salt thereof, or the pharmaceutical composition; a pharmaceutically acceptable carrier; and optionally, in combination with one or more other pharmaceutical compositions or with a clinically relevant immune modulator agent.

The invention discloses a lotus-derived polysaccharide targeted nano drug delivery system and application thereof. The lotus-derived polysaccharide targeted nano drug delivery system is composed of an active component and a carrier material wrapping the active component, the active ingredient is lotus root polysaccharide LSP-1, the LSP-1 is homogeneous polysaccharide extracted and purified from lotus roots, the molecular weight is 3.2 * 10 Da, and monosaccharide of the LSP-1 is composed of glucose, galactose and arabinose in a molar ratio of 5.2: 2.8: 1.0; the carrier material is an amphiphilic polymer, poly-beta-amino ester is taken as a main chain, a disulfide bond is introduced into the main chain, and the tail end of the polymer is modified with cell-penetrating peptide TAT and polyethylene glycol; the invention puts forward and verifies a new convergent collaborative immune regulation mechanism for the first time. The observed convergent synergistic effect is specific to the combination of the LSP-1 and the PBAE-based response type carrier, specific biochemical signal channel interaction exists between the LSP-1 and the PBAE-based response type carrier in mechanism, and the convergent synergistic effect can not be achieved through simple superposition of any immunomodulator and any nano-carrier.

The present invention refers to a fusion-polypeptide comprising a mutein of the α-subunit of human Interleukin (27), wherein at least one of the amino acid residues selected from the group consisting of sequence positions (160, 161, 162, 163, 164, 165, 180, 181) and (182) is / are mutated, and at least one pharmaceutically acceptable fusion partner. Further, the present invention relates to a nucleic acid molecule comprising a nucleotide sequence encoding said fusion-polypeptide, to a host cell containing said nucleic acid molecule and to an immune modulator comprising said fusion-polypeptide. The present invention further refers to the use of said fusion-polypeptide for the manufacture of a medicament for treating a disease, the fusion-polypeptide for use as a medicament or for use in the treatment or prevention of a disease. Further, the present invention relates to a method of treating a disease comprising the step of administering a composition comprising said fusion-polypeptide.

Provided are multispecific antigen binding proteins (e.g. bispecific antibodies or trispecific antibodies) or antigen binding fragments thereof. The multispecific antigen binding protein comprises a first antigen binding domain (B1), a first mask peptide (Ml), a second antigen binding domain (B2), a second mask peptide (M2), and an immune modulator. The M1 is linked to the B1 and impairs the binding of the B1 to the target of the B1. The M2 is linked to the B2 and impairs the binding of the B2 to the target of the B2. The immune modulator is linked to the N-terminus of the M1.

The use of low dose naltrexone as an adjuvant therapy to the use of biologic and / or immune modulator therapies is disclosed for the treatment of bowel and gastrointestinal disease, as well as for the treatment of abdominal and joint pain associated therewith.

The use of low dose naltrexone as an adjuvant therapy to the use of biologic and / or immune modulator therapies is disclosed for the treatment of bowel and gastrointestinal disease, as well as for the treatment of abdominal and joint pain associated therewith.

The present invention relates to muteins of the α-subunit of human Interleukin 12 as well as to muteins of the human Interleukin 12 comprising said α-subunit (p35) and a β-subunit. Further, the present invention is directed to a cDNA or DNA nucleic acid molecule or mRNA nucleic acid molecule comprising a nucleotide sequence encoding said muteins according to the present invention, to an engineered cell or virus, a recombinant protein, a fusion-protein, an immune modulator, a pharmaceutical composition comprising any of the muteins according to the present invention. Further, the present invention related to the use of the mutein for the manufacture of a medicament for treating a disease in a mammal, the mutein of the present invention for use as a medicament, a method of treating an Interleukin 12-mediated disease in a mammal, and a method for producing the mutein according to the present invention.

This present invention relates to small molecules which are biphenyl pyridine rigid compounds with polycyclic heterocycles therapeutically useful as immune modulators These compounds disrupt the PD-1 / PD-L1 checkpoint pathway and may also disrupt one or more related checkpoint pathways. These compounds are useful in treating, preventing or ameliorating disorders such as cancer or infections.

The present disclosure describes the use of immune modulators to promote nerve growth and regeneration, particularly in the context of nerve deficit stemming from trauma and disease. In particular, the disclosure provides for the use of CXCR4 antagonists, STAT3 activators, and an agent that increases levels of nitric oxide, either alone or in any combination of these drugs, in surgery performed to treat nerve deficit conditions, especially peripheral nerve deficit conditions caused by cut injury or tear injury, the method especially useful in bridging nerve gaps of 3 cm or longer.

A combination, composition, and method of use of (i) a conjugate comprising a targeted immune modulator and (ii) one or more immune checkpoint inhibitors for reprogramming M2-like macrophages into M1-like macrophages to reverse the pro-inflammatory response observed in cancer into an anti-inflammatory response. In at least one embodiment of a method of treating a subject having cancer, the subject is experiencing or at risk of experiencing cancer or cancer recurrence, and the step of administering a first treatment further comprises administering or applying to the subject a therapeutically effective amount of at least one compound or a pharmaceutically acceptable salt or hydrate thereof.

The present invention provides novel compositions and methods for inducing and / or activating regulatory T cells (Treg). Wherein a method of treating, inhibiting, and / or preventing a disease or disorder in a subject in need thereof, said method comprising administering at least two immune modulators to said subject, is disclosed.

The present invention relates to muteins of the α-subunit of human Interleukin 12 as well as to muteins of the human Interleukin 12 comprising said α-subunit (p35) and a β-subunit. Further, the present invention is directed to a cDNA or DNA nucleic acid molecule or mRNA nucleic acid molecule comprising a nucleotide sequence encoding said muteins according to the present invention, to an engineered cell or virus, a recombinant protein, a fusion-protein, an immune modulator, a pharmaceutical composition comprising any of the muteins according to the present invention. Further, the present invention related to the use of the mutein for the manufacture of a medicament for treating a disease in a mammal, the mutein of the present invention for use as a medicament, a method of treating an Interleukin 12-mediated disease in a mammal, and a method for producing the mutein according to the present invention.

The present disclosure provides a method of enhancing an immune response in a subject in need thereof, including administering an effective amount of an antigen with an immune modulator to the subject, wherein the immune modulator is a quaternary immunomodulatory nanoparticle (QIN). The present disclosure also provides the use of the QIN in the manufacture of a chimeric nanoparticle, a pharmaceutical composition and a medicament for treating a subject suffering from a cancer or virus infection.

This invention provides combinations of kynurenine and antigen presenting cells (APC) for modulating immune tolerance, wherein the combinations may be used to modulate an autoimmune response, which may be of use in the treatment of Type 1 Diabetes (TID)) or alopecia areata (AA). Uses of kynurenine and antigen presenting cells (APC) as an immune modulator for the treatment of TID or AA are also provided.

Immune responses in mammals are mediated by a complex interaction between peripheral blood cells called leukocytes and signaling molecules called cytokines. The present invention provides assay systems for investigative, diagnostic, and therapeutic use assessing immune response. These and other aspects of the invention yield powerful tools and methods for characterizing patient immune responses in various pathological conditions, as well as for assessing immune modulatory agents.

The invention discloses antisense oligonucleotide of a coding gene of targeted apoptosis inhibition protein BIRC6, and the antisense oligonucleotide and a nano-material carrier loaded with the antisense oligonucleotide can reduce expression ability of the BIRC6 gene in hematopoietic stem cells in a targeted manner, inhibit survival advantages of senescence hematopoietic stem cells and medullary system biased differentiation, reverse senescence of the hematopoietic stem cells, and inhibit apoptosis of the hematopoietic stem cells. The invention also discloses application of the antisense oligonucleotide and the nano-material carrier loaded with the antisense oligonucleotide in preparation of anti-aging drugs, drugs for promoting hematopoietic reconstitution after transplantation and immunomodulator drugs, and also discloses application of the antisense oligonucleotide and the nano-material carrier loaded with the antisense oligonucleotide in preparation of anti-aging drugs, drugs for promoting hematopoietic reconstitution after transplantation and immunomodulator drugs.

Synthetic oligosaccharides and mixtures thereof which resemble polysaccharides produced by plants, yeast and other fungi, bacteria, and algae are described. The oligosaccharides and compositions provided herein are useful as synbiotics, prebiotics, immune modulators, digestion aids, and food additives.

The present invention relates to an attenuated oncolytic virus including a recombinant polynucleotide, where the recombinant polynucleotide includes a 5'UTR, an internal ribosomal entry site (IRES), an encoding region, at least one protease cleavage site, and a 3' UTR, where the encoding region encodes an immune modulator polypeptide and uses of the attenuated oncolytic virus.